Japan Producer Prices Surge in May, Strengthening Expectations of BOJ Rate Hike 
Gold Prices Drop as Strong Dollar, Rising U.S.-Iran Tensions Weigh on Market Sentiment 
J.P. Morgan Sees Major Upside for Prysmian as Optical Fiber Prices Surge 
Sigma Healthcare Shares Slide Amid Preliminary Boots Acquisition Talks 
GM and Peak Energy Partner to Advance Sodium-Ion Battery Technology for Grid Storage 
Gold Prices Slide Toward Second Weekly Loss as Fed Rate Hike Expectations Weigh on Market 
Astera Labs and Rocket Lab Surge After Nasdaq-100 Inclusion Announcement 
Oil Prices Fall as Trump Signals Iran Deal, Reducing Supply Risk Concerns 
Oracle Stock Falls Despite Earnings Beat as Company Plans $40 Billion Financing for FY2027 
South Korea Signals Possible Interest Rate Hike as Inflation Remains Elevated 
Kremlin Says New EU Sanctions Won’t Hurt Russian Banks 
Coupang Hit With Record $409 Million Fine Over Data Breach Affecting 33 Million Users 
SpaceX IPO Demand Surges Past $250 Billion Ahead of Historic Market Debut 
Changchun Targets EV Growth as China’s Auto Industry Consolidation Accelerates 
New Zealand Unemployment and Inflation Debate Intensifies Ahead of 2026 Election 
OpenAI May Slash AI Service Prices Amid Growing Rivalry With Anthropic 
ECB Keeps July Rate Options Open Amid Iran War Energy Price Risks 
Samsung Biologics and Biogen, an American biotechnology company, based in Cambridge, Massachusetts, signed a deal for the transfer of stake in Samsung Boiepis. The South Korean biotech firm headquartered in Songdo, Incheon, is buying all of Biogen’s stake in the biopharma company.
Samsung Bioepis was formed in 2012 via a joint venture between Samsung Biologics and Biogen. The latter owned a 15% stake at first, and in 2018, the percentage was increased to 50% as it extended its controlling rights in the company.
As per The Korea Herald, the acquisition of Biogen’s stake is predicted to help boost Samsung Biologic’s competitiveness in the global bio market. The value of the deal is ₩2.7 trillion or around $2.3 billion.
The total shares acquired are 10,341,852 units, and Samsung Biologics stated that the company’s board of directors approved the transaction. The payments for the stakes are set to be made in installments and will be paid over the next two years.
The full ownership of the shares will take effect once the first payment of $1 billion is completed. It was revealed that it was Biogen that forwarded a request for the buyout deal. Despite the acquisition, both companies said they would continue to work as close partners.
“We are thankful to Samsung Biologics for a productive collaboration since 2012,” Biogen’s chief executive officer, Michel Vounatsos, said in a press release. “We believe biosimilars are essential to help sustain healthcare systems and represent an important value creation opportunity for Biogen.”
With the transaction, Samsung Biologics Co. will take over and be in full control of Samsung Bioepis Co. since the deal is for the entire holdings of Biogen’s shares. Pulse News reported that the transfer of shares is set to take place on April 30, 2022.
Meanwhile, Samsung Bioepis is currently developing five biosimilar drugs that it will be launching worldwide. One of them is just waiting for approval and ready for marketing. The four other drugs are in the third phase of clinical trials. Two of the medicines are for oncology, and three are formulated for autoimmune.
